Scandion Oncology appoints Jan Stenvang, Ph.D., Chief Scientific Officer and member of Executive Management

Jan Stenvang is co-founder of Scandion Oncology and has more than 20 years of experience in cancer research.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, strengthens its Executive Management with the inclusion of Jan Stenvang, who is appointed Chief Scientific Officer (CSO) reporting directly to CEO Francois Martelet.

A co-founder of Scandion, Jan Stenvang led the initial research and discoveries upon which Scandion is based. He has headed the company’s research and early development activities ever since and has played a pivotal role in e.g. the planning and execution of the development of Scandion’s lead compound SCO-101. In his new role he will continue this work, also focusing on potential new indications that Scandion could pursue.

With a master’s degree and Ph.D. in Molecular and Cellular Biology, Jan Stenvang has specialized in translational cancer research particularly focusing on drug resistance and biomarker identification. Before co-founding Scandion, he spent most of his career in academia as e.g. Group Leader and Associate Professor at Copenhagen University and also as Group Leader at the biotech company Santaris Pharma. Combined, Jan Stenvang has more than 20 years of experience in cancer research.

“We are delighted to appoint Jan CSO and member of Executive Management allowing us to utilize his expertise even more in the management and development of Scandion. Jan is a distinguished researcher and expert in the field of cancer drug resistance and his contributions will be crucial in our work to bring forward new and better cancer treatments”, says Francois Martelet, CEO of Scandion.

“It is a great pleasure for me to be taking this new role and also contribute as a member of Executive Management in Scandion. We have the potential to make a huge difference for patients and I am excited to contribute to the research and development of medicines that can revert cancer drug resistance”, says Jan Stenvang.

For further information please contact:

Johnny Stilou, CFO

Phone: +45 2960 3532

E-mail: jos@scandiononcology.com

The information was provided by the contact person above for publication on January 18, 2023, at 14.00 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). 

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.